Business Wire - December 2, 2008
WAKEFIELD, Mass.--The Pink Sheet, one of the leading publications in the pharmaceutical and biotechnology industries, published an article in its December 1, 2008 issue, discussing how managed care payers are now scrutinizing new cancer, HIV, and rare diseases therapies for their healthcare value. This represents a significant change from the past, where drugs in these categories had been largely "exempted" from healthcare value scrutiny.
The article extensively quotes Bruckner Group partner David Balekdjian, one of the country's foremost thought-leaders on healthcare value issues and strategy. Further, the article highlights The Bruckner Group's industry-leading and highly innovative approach, which helps pharma and biotech companies develop new drugs that deliver a differentiating and compelling healthcare value proposition to payers.
"It is tremendously gratifying to all of us at Bruckner to see public recognition in The Pink Sheet of Bruckner's industry-leading expertise helping pharma and biotech companies develop drugs that deliver high healthcare value to payers," said Michael J. Russo, President, The Bruckner Group. "While Bruckner's clients understand the tremendously differentiating impact that Bruckner has had on their clinical and commercialization pathways and processes, there are many pharma and biotech companies that still are following legacy approaches that sorely need re-tooling. Bruckner's clients have experienced tremendous successes using Bruckner's approach, because we construct a highly effective and cost-efficient pathway that maximizes a drug's healthcare value-satisfying payers' needs, alongside the needs of the FDA, physicians, and patients," Michael Russo indicated. "Bruckner's approach not only minimizes risk, but also significantly increases the likelihood of market success and revenue maximization."
Many pharma and biotech companies-such as Pfizer, GlaxoSmithKline, Novartis, Johnson & Johnson, Sanofi-Aventis, Abbott, Lilly, AstraZeneca/MedImmune, Wyeth, Roche, Takeda, Eisai, and Astellas, as well as many development-stage biotech companies, are developing new drugs in oncology, immunology, neurology, autoimmune diseases, HIV, and infectious diseases. These areas are being especially targeted by payers for a new round of healthcare value scrutiny, which lays the basis for payers' access decisions. Successful companies will be the ones that engage a development pathway that truly aligns with payers' healthcare value needs.
As outlined in "Weighing The Outcomes," the widely-circulated feature article by Michael Russo and David Balekdjian in the February 2008 issue of Nature Biotechnology, The Bruckner Group offers a tremendous value proposition to its clients: Bruckner helps its clients get it right the first time-and at relatively modest cost. By satisfying payers proactively, payers can become partners, not enemies, and ensure that as many patients as appropriate will be treated with the new drug. This is the clear pathway to revenue maximization.
About The Bruckner Group: The Bruckner Group (www.brucknergroup.com), the industry leader in healthcare value strategy, assists pharmaceutical and biotechnology company executives in developing business models, enterprise-wide processes, and individual product strategies that produce new drugs with high healthcare value, meeting the needs of payers, employers, physicians, and patients. In addition to healthcare value strategy, The Bruckner Group assists pharma and biotech executives on a broad range of strategy issues, including payer strategy, product development strategy, strategic marketing, pricing, and corporate development initiatives.
Contacts
The Bruckner Group | David Balekdjian, 781-245-4454, x222
081202
BW081209
Copyright © 2008 - Business Wire. All rights reserved. Reproduced with permission. Reproduction of this article (other than one copy for personal reference) must be cleared through the Business Wire, Permissions Desk, Business Wire, 1185 Avenue of the Americas, 3rd Floor, New York, NY 10036; Tel: (212) 575-8822; FAX: (212) 575-1854. http://www.businesswire.com.
AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Broadway Cares/Equity Fights AIDS, Elton John AIDS Foundation, the National Library of Medicine, Pacific Life Foundation and donations from users like you.
Always watch for outdated information. This article first appeared in 2008. This material is designed to support, not replace, the relationship that exists between you and your doctor.
AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.
Copyright ©1980, 2008. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .